Caxton Associates LLP Novavax Inc Transaction History
Caxton Associates LLP
- $2.87 Trillion
- Q1 2025
A detailed history of Caxton Associates LLP transactions in Novavax Inc stock. As of the latest transaction made, Caxton Associates LLP holds 24,681 shares of NVAX stock, worth $155,243. This represents 0.01% of its overall portfolio holdings.
Number of Shares
24,681Holding current value
$155,243% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding NVAX
# of Institutions
298Shares Held
90.3MCall Options Held
5.76MPut Options Held
6.65M-
Vanguard Group Inc Valley Forge, PA15.7MShares$98.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$74.5 Million0.0% of portfolio
-
Shah Capital Management11.1MShares$70 Million33.15% of portfolio
-
State Street Corp Boston, MA7.04MShares$44.3 Million0.0% of portfolio
-
Coatue Management LLC New York, NY3.84MShares$24.1 Million0.13% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $492M
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...